Vistusertib联合紫杉醇治疗高级别浆液性卵巢癌与肺鳞癌的I期研究
本I期试验评估双m-TORC1/2抑制剂vistusertib联合周疗紫杉醇在晚期实体瘤中的剂量递增及在高级别浆液性卵巢癌(HGSOC)和肺鳞癌(sqNSCLC)中的扩展队列。确定RP2D后,HGSOC扩展队列RECIST缓解率52%、GCIG CA125缓解率64%,中位PFS 5.8个月;sqNSCLC扩展队列需降低vistusertib剂量至25mg bd,RECIST缓解率35%,中位PFS 5.8个月。
要点
- RP2D为紫杉醇80mg/m2联合vistusertib 50mg bd 3/7天,6/7周方案。
- HGSOC扩展队列RECIST缓解率52%,CA125缓解率64%,mPFS 5.8个月。
- sqNSCLC扩展队列需将vistusertib降至25mg bd,RECIST缓解率35%,mPFS 5.8个月。
核心结论
- Vistusertib联合周疗紫杉醇在HGSOC和sqNSCLC中显示出高活性和可耐受性。
研究设计与样本
- I期试验含剂量递增(22例晚期实体瘤)及HGSOC(25例)和sqNSCLC(40例)扩展队列。
- 紫杉醇80mg/m2周疗6/7周,联合vistusertib两种间歇方案:A方案3/7天bd,B方案2/7天bd。
主要发现
- 剂量限制性毒性:A方案为乏力和黏膜炎,B方案为皮疹。
- HGSOC扩展:RECIST缓解率13/25(52%),GCIG CA125缓解率16/25(64%),mPFS 5.8个月(95%CI 3.28-18.54)。
- sqNSCLC扩展:RP2D耐受性不佳,vistusertib减至25mg bd后23例中RECIST缓解率8/23(35%),mPFS 5.8个月(95%CI 2.76-21.25)。
关键数值与推荐
- RP2D:紫杉醇80mg/m2联合vistusertib 50mg bd 3/7天,6/7周。
临床怎么用
- HGSOC可考虑vistusertib联合周疗紫杉醇,但需注意乏力、黏膜炎和皮疹。
- sqNSCLC使用该方案需将vistusertib剂量降至25mg bd以管理毒性。
局限性
- I期试验样本量有限,扩展队列非随机对照。
- sqNSCLC扩展队列中RP2D耐受性不佳,需调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer. We hypothesised that inhibiting p-S6K signalling with the dual m-TORC1/2 inhibitor in patients receiving weekly paclitaxel could improve outcomes in such patients. PATIENTS AND METHODS: In dose escalation, weekly paclitaxel (80 mg/m2) was given 6/7 weeks in combination with two intermittent schedules of vistusertib (dosing starting on the day of paclitaxel): schedule A, vistusertib dosed bd for 3 consecutive days per week (3/7 days) and schedule B, vistusertib dosed bd for 2 consecutive days per week (2/7 days). After establishing a recommended phase II dose (RP2D), expansion cohorts in high-grade serous ovarian cancer (HGSOC) and squamous non-small-cell lung cancer (sqNSCLC) were explored in 25 and 40 patients, respectively. RESULTS: The dose-escalation arms comprised 22 patients with advanced solid tumours. The dose-limiting toxicities were fatigue and mucositis in schedule A and rash in schedule B. On the basis of toxicity and pharmacokinetic (PK) and pharmacodynamic (PD) evaluations, the RP2D was established as 80 mg/m2 paclitaxel with 50 mg vistusertib bd 3/7 days for 6/7 weeks. In the HGSOC expansion, RECIST and GCIG CA125 response rates were 13/25 (52%) and 16/25 (64%), respectively, with median progression-free survival (mPFS) of 5.8 months (95% CI: 3.28-18.54). The RP2D was not well tolerated in the SqNSCLC expansion, but toxicities were manageable after the daily vistusertib dose was reduced to 25 mg bd for the following 23 patients. The RECIST response rate in this group was 8/23 (35%), and the mPFS was 5.8 months (95% CI: 2.76-21.25). DISCUSSION: In this phase I trial, we report a highly active and well-tolerated combination of vistusertib, administered as an intermittent schedule with weekly paclitaxel, in patients with HGSOC and SqNSCLC. CLINICAL TRIAL REGISTRATION: ClinicialTrials.gov identifier: CNCT02193633.
引用
- Basu B, Krebs MG, Sundar R, et al. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Ann Oncol. 2018. PMID: 30016392. doi:10.1093/annonc/mdy245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。